Back to Search
CRAIG BUNNELL, MD
MD
Medical Oncology Physician
NPI: 1982679767IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
75976(MA)
Education
HARVARD MEDICAL SCHOOL
Class of 1990
Research & Publications (20)
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
PMID 18650153·Clin Breast Cancer·2008
3-trial
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.
PMID 11761451·Cancer Chemother Pharmacol·2001
3-trial
Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations.
PMID 17879984·J Pharm Sci·2008
8-other
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
PMID 17606975·J Clin Oncol·2007
3-trial
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
PMID 17606972·J Clin Oncol·2007
3-trial
Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer.
PMID 19442346·J Soc Integr Oncol·2006
2-rct
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
PMID 16243442·Int J Radiat Oncol Biol Phys·2006
3-trial
Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
PMID 16184455·Breast Cancer Res Treat·2005
8-other
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.
PMID 16293876·J Clin Oncol·2005
8-other
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
PMID 16293865·J Clin Oncol·2005
3-trial
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
PMID 16192581·J Clin Oncol·2005
3-trial
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
PMID 12885806·J Clin Oncol·2003
3-trial
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
PMID 12784331·Cancer·2003
8-other
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
PMID 12506169·J Clin Oncol·2003
3-trial
Quality of life issues among women undergoing high-dose chemotherapy for breast cancer.
PMID 15687635·Breast Dis·2001
8-other
New cytotoxic agents and schedules for advanced breast cancer.
PMID 11498829·Semin Oncol·2001
6-review
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
PMID 11352965·J Clin Oncol·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, DANA-FARBER CANCER INSTITUTE
BOSTON, MA 02115 - Phone
- (617) 632-3800
Quick Facts
- NPI
- 1982679767
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile